HELEN HESLOP to Adolescent
This is a "connection" page, showing publications HELEN HESLOP has written about Adolescent.
Connection Strength
0.728
-
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.
Score: 0.061
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.027
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.021
-
Pediatric blood and marrow transplantation: state of the science. Bone Marrow Transplant. 2008 Jan; 41(2):97.
Score: 0.018
-
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
Score: 0.018
-
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33.
Score: 0.015
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 08 10; 42(23):2769-2779.
Score: 0.014
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
Score: 0.014
-
Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55.
Score: 0.014
-
Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev. 2003 Feb; 29(1):3-10.
Score: 0.013
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
Score: 0.012
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
Score: 0.012
-
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 01; 98(7):2052-8.
Score: 0.012
-
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
Score: 0.012
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.012
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.011
-
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
Score: 0.011
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.011
-
Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
Score: 0.011
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.010
-
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
Score: 0.010
-
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
Score: 0.010
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
Score: 0.010
-
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
Score: 0.010
-
Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
Score: 0.009
-
Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
Score: 0.009
-
Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
Score: 0.009
-
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
Score: 0.009
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.009
-
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
Score: 0.008
-
Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
Score: 0.008
-
Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
Score: 0.008
-
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
Score: 0.008
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.008
-
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
Score: 0.008
-
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
Score: 0.008
-
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
Score: 0.008
-
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
Score: 0.007
-
XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
Score: 0.007
-
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
Score: 0.007
-
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
Score: 0.007
-
Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 Feb; 13(2):221-3.
Score: 0.007
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.007
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.007
-
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013 Feb 15; 95(3):519-26.
Score: 0.007
-
Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
Score: 0.006
-
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
Score: 0.006
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.006
-
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
Score: 0.006
-
Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol. 1991 Feb; 77(2):237-44.
Score: 0.006
-
Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
Score: 0.006
-
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
Score: 0.006
-
Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
Score: 0.005
-
The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81.
Score: 0.005
-
In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep; 74(4):1374-80.
Score: 0.005
-
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
Score: 0.005
-
Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol. 1989 Jun; 72(2):122-6.
Score: 0.005
-
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
Score: 0.005
-
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
Score: 0.005
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.005
-
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
Score: 0.005
-
In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J Immunol. 1988 May 15; 140(10):3461-6.
Score: 0.005
-
A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5.
Score: 0.004
-
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86.
Score: 0.004
-
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
Score: 0.004
-
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007 Mar 15; 109(6):2657-62.
Score: 0.004
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.004
-
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
Score: 0.004
-
Allogeneic bone marrow transplantation at Christchurch 1979-1985. N Z Med J. 1986 May 14; 99(801):318-21.
Score: 0.004
-
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93.
Score: 0.004
-
Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005 Dec; 36(11):1001-8.
Score: 0.004
-
Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant. 2005 Nov; 11(11):912-20.
Score: 0.004
-
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8.
Score: 0.004
-
Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant. 2003 Nov; 9(11):698-705.
Score: 0.003
-
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
Score: 0.003
-
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
Score: 0.003
-
Energy expenditure in children undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Jul; 30(2):125-30.
Score: 0.003
-
Guillain-Barr? syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(6):515-7.
Score: 0.003
-
Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy. 2002; 4(3):253-8.
Score: 0.003
-
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
Score: 0.003
-
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant. 2001 Jan; 27(2):155-62.
Score: 0.003
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.003
-
Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999 Oct; 24(7):735-9.
Score: 0.003
-
Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 Feb; 23(3):277-82.
Score: 0.002
-
Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. Pediatr Radiol. 1998 Jul; 28(7):492-6.
Score: 0.002
-
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15; 91(8):2925-34.
Score: 0.002
-
Hepatic arterial resistance index--an indicator of diffuse liver disease in children treated with bone marrow transplantation. Clin Radiol. 1997 Dec; 52(12):903-6.
Score: 0.002
-
Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995 Dec; 9(12):1990-6.
Score: 0.002
-
T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient. Cancer Immunol Immunother. 1995 Aug; 41(2):104-10.
Score: 0.002
-
Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35.
Score: 0.002
-
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
Score: 0.002
-
Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
Score: 0.002
-
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
Score: 0.002
-
Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. Bone Marrow Transplant. 1992 Dec; 10(6):521-7.
Score: 0.002
-
IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8.
Score: 0.002
-
A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer. 1989 Oct; 60(4):610-5.
Score: 0.001
-
Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
Score: 0.001